PHC, Inc. AMEX:PHC   PHC Announces New Stock Buyback Program PHC, Inc., d/b/a Pioneer Behavioral Health (NYSE AMEX: PHC), a leading provider of inpatient and outpatient behavioral health services, announced today that its Board of Directors has authorized the buyback of up to 1 million shares of the Companys Class A common stock on the open market over the course of its next fiscal year, which begins July 1, 2009. The current Stock Buyback program, under which the Company has purchased approximately 400,000 shares, expires June 30, 2009.

Enzo Biochem, Inc. NYSE:ENZ   Enzo Biochem Life Sciences Unit Awarded Patent For Increasing Detectability of Proteins and Pathogens Enzo Biochem, Inc., a biotechnology company specializing in gene identification and genetic and immune regulation technologies for diagnostic and therapeutic applications and laboratory services, announced today that its subsidiary, Enzo Life Sciences, Inc., has been granted a new patent by the U.S. Patent and Trademark Office that will complement existing proprietary technologies that have applications in the molecular diagnostics and life sciences marketplaces.

ImmunoCellular Therapeutics, Ltd OTCBB:IMUC   ImmunoCellular Therapeutics Announces Issuance of Japanese Patent Covering Its Lead Antibody Product Candidate ICT-109 For Treatment of Small Cell Lung Cancer ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC - News), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today the issuance of a Japanese patent relating to the companys monoclonal antibody therapeutics. Patent No. 4287147, entitled Monoclonal Antibodies and Cell Surface Antigens for the Detection and Treatment of Small Cell Lung Cancer, covers the use of IMUCs proprietary antibodies in diagnosing and treating patients with small cell lung cancer (SCLC) using the companys lead antibody product candidate, ICT-109............